ERYTHROMYCIN capsule, delayed release pellets United States - English - NLM (National Library of Medicine)

erythromycin capsule, delayed release pellets

mayne pharma inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes. listeriosis caused by listeria monocytogenes. pertussis (whooping cough) caused by bordetella pertussis. erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible indivi

LEVORA- levonorgestrel and ethinyl estradiol kit United States - English - NLM (National Library of Medicine)

levora- levonorgestrel and ethinyl estradiol kit

mayne pharma inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - levora 0.15/30-28 is indicated for use by females of reproductive potential to prevent pregnancy. levora 0.15/30-28 is contraindicated in females who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: – smoke, if over age 35 [see boxed warning and warnings (1)]. – have current or history of deep vein thrombosis or pulmonary embolism [see warnings (1)]. – have cerebrovascular disease [see warnings (1)]. – have coronary artery disease [see warnings (1)]. – have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings (1)]. – have inherited or acquired hypercoagulopathies [see warnings (1)]. – have uncontrolled hypertension or hypertension with vascular disease [see warnings (4)]. – have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or vascular disease or other end-or

KAPANOL morphine sulfate pentahydrate 10 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

kapanol morphine sulfate pentahydrate 10 mg capsule blister pack

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - capsule, modified release - excipient ingredients: purified talc; purified water; maize starch; gelatin; sucrose; methacrylic acid copolymer; ethylcellulose; hypromellose; macrogol 6000; diethyl phthalate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

KAPANOL morphine sulfate pentahydrate 100 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

kapanol morphine sulfate pentahydrate 100 mg capsule blister pack

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - capsule, modified release - excipient ingredients: sucrose; ethylcellulose; purified water; gelatin; macrogol 6000; maize starch; hypromellose; purified talc; diethyl phthalate; methacrylic acid copolymer; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

KAPANOL morphine sulfate pentahydrate 50 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

kapanol morphine sulfate pentahydrate 50 mg capsule blister pack

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 50 mg - capsule, modified release - excipient ingredients: hypromellose; methacrylic acid copolymer; gelatin; sucrose; purified talc; maize starch; purified water; ethylcellulose; diethyl phthalate; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

KAPANOL morphine sulfate pentahydrate 20 mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

kapanol morphine sulfate pentahydrate 20 mg capsule blister pack

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; macrogol 6000; gelatin; purified water; diethyl phthalate; sucrose; ethylcellulose; maize starch; hypromellose; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain: kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness: kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

ACTIKERALL fluorouracil and salicylic acid 0.5% / 10% (w/w) topical solution, bottle Australia - English - Department of Health (Therapeutic Goods Administration)

actikerall fluorouracil and salicylic acid 0.5% / 10% (w/w) topical solution, bottle

mayne pharma international pty ltd - fluorouracil, quantity: 0.5 g; salicylic acid, quantity: 10 g - solution - excipient ingredients: butyl methacrylate/methyl methacrylate copolymer (3:1); ethyl acetate; dimethyl sulfoxide; ethanol absolute; pyroxylin - actikerall is indicated for the topical treatment of solar (actinic) keratosis

UROCARB bethanechol chloride 10 mg tablet Australia - English - Department of Health (Therapeutic Goods Administration)

urocarb bethanechol chloride 10 mg tablet

mayne pharma international pty ltd - bethanechol chloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: erythrosine; magnesium stearate; wheat starch; amaranth; lactose monohydrate; acacia; hydrogenated vegetable oil - acute post-operative and postpartum non-obstructive urinary retension, and neurogenic atony of the urinary bladder with retension. bethanechol has no clinically significant nicotinic stimulant activity.

NEXTSTELLIS estetrol (as monohydrate) 14.2 mg / drospirenone 3 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

nextstellis estetrol (as monohydrate) 14.2 mg / drospirenone 3 mg tablet blister pack

mayne pharma international pty ltd - estetrol monohydrate, quantity: 15 mg (equivalent: estetrol, qty 14.2 mg); drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: magnesium stearate; titanium dioxide; hypromellose; hyprolose; purified talc; hydrogenated cottonseed oil; lactose monohydrate; maize starch - nextstellis is indicated for use by women of reproductive potential to prevent pregnancy.